Global Breakthrough: FGC2.3 Feline Vocalization Project Nears Record Reads — Over 14,000 Scientists Engage With Cat-Human Translation Research

Global Breakthrough: FGC2.3 Feline Vocalization Project Nears Record Reads — Over 14,000 Scientists Engage With Cat-Human Translation Research

MIAMI, FL — The FGC2.3: Feline Vocalization Classification and Cat Translation Project, authored by Dr. Vladislav Reznikov, has crossed a critical scientific milestone — surpassing 14,000 reads on ResearchGate and rapidly climbing toward record-setting levels in the field of animal communication and artificial intelligence. This pioneering work aims to develop the world’s first scientifically grounded…

Tariff-Free Relocation to the US

Tariff-Free Relocation to the US

EU, China, and more are now in the crosshairs. How’s next? It’s time to act. The Trump administration has announced sweeping tariff hikes, as high as 50%, on imports from the European Union, China, and other major markets. Affected industries? Pharmaceuticals, Biotech, Medical Devices, IVD, and Food Supplements — core sectors now facing crippling costs,…

Global Distribution of the NRAs Maturity Levels as of the WHO Global Benchmarking Tool and the ICH data

Global Distribution of the NRAs Maturity Levels as of the WHO Global Benchmarking Tool and the ICH data

This study presents the GDP Matrix by Dr. Vlad Reznikov, a bubble chart designed to clarify the complex relationships between GDP, PPP, and population data by categorizing countries into four quadrants—ROCKSTARS, HONEYBEES, MAVERICKS, and UNDERDOGS depending on National Regulatory Authorities (NRAs) Maturity Level (ML) of the regulatory affairs requirements for healthcare products. Find more details…

Quirky Graphene May Enhance Proton Therapy Precision

Quirky Graphene May Enhance Proton Therapy Precision

A new twist on pencil graphite might be a key ingredient to better cancer treatment, scientists in Singapore say. Graphite is composed of stacked layers of graphene, a single-atom-thick sheet of carbon atoms arranged in repeating hexagonal rings. Now add pentagons, septagons, and octagons of carbon atoms into the sheet, and you’re looking at a new form of ultrathin carbon that promises to sharpen beams of subatomic particles used in proton therapy.

Ultrathin foils of carbon materials have been used for decades in proton therapy to filter particles into high-precision beams meant to kill tumors. But, they take time to make and often contain impurities from the manufacturing process that lower the precision of the beam. In research described in Nature Nanotechnology, Jiong Lu and his colleagues at National University of Singapore and in China developed a technique that can grow a 200-millimeter sheet of a new kind of ultrathin carbon material in just 3 seconds, with no detectable impurities.

Proton therapy is a noninvasive radiation treatment in which hydrogen ions are accelerated through a cyclotron to form a high-energy beam used to destroy DNA in tumors. In a cyclotron, an electromagnetic field accelerates ions of molecular hydrogen, which spiral outward as they pick up speed. They then strike a carbon foil that strips away the hydrogen’s electrons, leaving protons that exit the machine as a high-energy beam. Proton therapy is often preferred as a treatment because of its precision. The sharp beam eliminates tumors while preserving healthy tissue. The new carbon promises an even sharper and more energy-intense beam, potentially making the treatment more potent.

The benefits of the new material, called ultra-clean monolayer amorphous carbon (UC-MAC), are derived from its disordered ring structure, which contrasts with the perfect hexagonal rings in graphene. The structures present in UC-MAC create tiny pores in the material that are only one-tenth of a nanometer wide. The researchers have found a way to fine-tune these angstrom-scale pores to control how the material filters hydrogen ions, in order to produce proton beams with less scattering.

Nanograins and Nanopores

The new technique starts with depositing a thin film of copper on top of a sapphire wafer inside a chamber filled with high-density plasma. Depending on the temperature of the copper and the rate at which it’s deposited, irregular crystals a couple dozen nanometers in size called nanograins form. The nanograins provide the right conditions for UC-MAC to grow, and eventually, a complete layer of the atom-thick carbon material crystallizes on top of the copper. This growth happens in just three seconds, more than an order of magnitude faster than previous methods used to grow carbon foils.

Huihui Lin, a research scientist at Singapore’s Agency for Science, Technology and Research who worked on the project, explains that the synthesis’s rapid speeds come from the high density of the nanograins that form on the copper, and from the plasma in the growth chamber, which provides high quantities of particles that react with the substrate to form the carbon structure.

Despite its potential importance in cancer treatment though, Lin says that UC-MAC was originally designed with different applications in mind. “We tried it in electronics and optical devices, and after three years of work, we discovered its unique advantage as a membrane for producing precision proton beams,” he explains.

Because of the angstrom-size pores in the material, the team discovered that UC-MAC was uniquely suited to turning molecular hydrogen ions into protons. Accelerating molecular hydrogen ions through the cyclotron instead of already-filtered protons increased the quantity of protons in the beam in a given amount of time, by an order of magnitude.

Lin thinks it will still take time to get the material to the point of commercialization. He explains that like many other 2D materials, “you need tens of steps” to grow the carbon on the substrate. So, simplifying the process is crucial to getting closer to commercialization. Eventually though, the material may make proton therapy a more widely available treatment option. “The UC-MAC makes proton beams more tunable [and] affordable,” says Lin.

Speech BCI Enhancement through Machine Learning Competition

Speech BCI Enhancement through Machine Learning Competition

For the next five months, machine learning gurus can try to best predict the speech of a brain-computer interface (BCI) user who lost the ability to speak due to a neurodegenerative disease. Competitors will design algorithms that predict words from the patient’s brain data. The individual or team whose algorithm makes the fewest errors between predicted sentences and actual attempted sentences will win a US $5,000 prize.

The competition, called Brain-to-text ‘25, is the second-annual public, open-source brain-to-text competition hosted by a research lab part of the BrainGate consortium, which has been pioneering BCI clinical trials since the early 2000s. This year, the competition is being run by the University of California Davis’s Neuroprosthetics Lab. (A group from Stanford University hosted the first competition using brain data from a different BCI user.)

For two years, the UC Davis research team has collected brain data from a 46-year-old man, Casey Harrell, whose speech is unintelligible except to his regular caregivers. Once the speech BCI was trained on Harrell’s brain data, it could decode what he was trying to say over 97 percent of the time and could instantly synthesize his own voice, as previously reported by IEEE Spectrum.

Decoding Speech from Brain Data

Parsing words from brain data is a two-step process: The algorithm must first predict speech sounds, called phonemes, from neural data. Then it must predict words from the phonemes. Competitors will train their algorithms on the brain data corresponding to 10,948 sentences with accompanying transcripts of what Harrell was attempting to say.

Then comes the real test: The algorithms must predict the words in 1,450 sentences from brain data withheld from the training data. The difference between the final set of predicted words and the words that Harrell attempted to say is called the word error rate—the lower the word error rate, the better the speech BCI works, overall.

Researchers reported a 6.70 percent word error rate, which they hope the public can beat. The goal of the competition is to attract machine learning experts who may not realize how valuable their skills are to speech BCIs, says Nick Card, a postdoctoral researcher at UC Davis leading both the clinical trial and the competition.

“We could sit on this data and hide it internally and make more discoveries with it over time,” says Card. “But if the goal is to help make this technology mature faster to help the people who need to benefit from this technology right now, then we want to share it and we want people to help us solve this problem.”

The public invite into the research world is “an awesome development” that is “long overdue” in the BCI space, said Konrad Kording, a professor at the University of Pennsylvania who researches the brain using machine learning, and who is not involved in the research or competition.

This year, Card and his fellow researchers have raised the bar by lowering the starting word error rate with their own high-performing algorithm. The first brain-to-text competition in 2024 began with the Stanford University group posting an error rate of 11.06 percent and finished with the competition winner achieving 5.77 percent. Also new this year are cash prizes for lowest error rates and the most innovative approach, provided by BCI company Blackrock Neurotech, whose electrodes and recording hardware have been used by BrainGate clinical trials since 2006.

Ethical Concerns in BCI Data Sharing

BCIs have long served as a bridge between neuroscience, medicine, and machine learning. And while machine learning has a tradition of open-source research, medical research is bound by patient confidentiality.

The main concern with public brain data is that the patient will be identified, says bioethicist Veljko Dubljević, a professor of both philosophy and science, technology, and society at North Carolina State University.

That concern is moot in this case because Harrell went public in August 2024, roughly five years after he began losing muscle tone because of amyotrophic lateral sclerosis (also known as Lou Gehrig’s disease). In 2023, neurosurgeons at UC Davis implanted four electrode arrays with a total of 256 electrodes into the top layers of his brain. Harrell used his speech BCI in an interview with the New England Journal of Medicine last year to explain how the disease feels like being in a “slow-motion car crash.” Harrell said at the time that “it was very painful to lose the ability to communicate, especially with my daughter.”

The speech BCI was trained on data collected while Harrell conducted in-lab experiments and while he spoke casually with family and friends. But competitors of Brain-to-text ‘25 will not see any “personal use” data recorded while Harrell spoke casually and extemporaneously, Card says.

While this is a “good precaution,” Dubljević says, he wonders if Harrell realizes what it means to have someone’s sensitive medical data in the public domain for years. The “noise” of today’s BCIs could be decoded into meaningful personal information in 50 years, for instance, in a way similar to how blood donated in 1955 can now also reveal details about a person’s DNA. (DNA profiling wasn’t established until the 1980s.) Dubljević recommends limiting the data storage to five years.

Speech BCIs decode the intended movements of a person’s jaw and mouth muscles, in the same way a BCI for an arm or hand prosthesis decodes intended movements. But speech BCIs feel more personal than BCIs that control a hand prostheses, Dubljević says. Speech is closer to “the innermost sanctum of a person,” he says. “There’s quite a lot of fear about mind reading, right?”

“As a researcher who wants to see science technology deployed for the public good, I want the technology not to be hyped up” in order to avoid a backlash, Dubljević says.

Cash Prizes for Innovative BCI Solutions

The two lowest word error rates come with $5,000 and $3,000 cash prizes, respectively, and the most innovative approach will win $1,000.

The last category is meant to encourage out-of-the-box ideas with great potential, if given more data or more time. Stacking 10 multiples of the same algorithm is a common way to force a more accurate overall performance, but it costs 10 times as much computational power and, “quite frankly, it’s not a very creative solution, right?” Card says.

The innovative category is likely to attract the usual crowd of academic and industry BCI scientists, who enjoy finding creative solutions, Kording says.

But the top slots will likely go to coders with no background in BCIs and who sport a “street fighting” style of machine learning, as Kording calls it. These “street fighters” focus on speed over ingenuity. In practice, the best BCI algorithms, Kording said, are “usually not really driving from a deep knowledge of how brains work. They’re driving from a deep understanding of how machine learning works.”

That said, both the traditional BCIs and new entrants are important parts of the science engineering ecosystem, Kording says. With the corners full, the competition is slated to be an exciting battle.

An In-Depth Examination of Creatine Use in Combat Sports

An In-Depth Examination of Creatine Use in Combat Sports

A comprehensive review published in the Journal of Dietary Supplements examines the effects of creatine supplementation on athletes in combat sports, highlighting potential benefits such as increased muscular strength and fat-free mass. The study addresses concerns about weight gain and suggests that increases are modest and potentially advantageous. It calls for future research with greater methodological rigor to further understand creatine’s impact on performance and body composition.

Generative AI-Created Medications Take on Superbugs

Generative AI-Created Medications Take on Superbugs

Some today fear that artificial intelligence will one day destroy humanity. But if the rise of the machines doesn’t get us, drug-resistant bacteria just might. These microscopic killers already claim millions of lives each year worldwide, and the world’s arsenal of effective antibiotics is dwindling.

But could one threat be trained perhaps to help stave off the other? A study published today in the journal Cell certainly suggests the possibility. A team led by Jim Collins, MIT professor of biological engineering, showed how generative AI algorithms trained on vast datasets of antibacterial substances could dream up millions of previously unimagined molecules with predicted microbe-killing power—some of which proved potent in mouse experiments.

The researchers synthesized a small subset of these AI-designed molecules and found them lethal to superbugs responsible for drug-resistant gonorrhea and stubborn staphylococcus skin infections.

“It’s a great addition to this emerging field of using AI for antibiotic discovery,” says César de la Fuente, a synthetic biologist at the University of Pennsylvania who was not involved in the research. “It shows quite well how generative AI can produce molecules with real-world activity,” he adds. “It’s elegant and potentially clinically meaningful.”

A social-enterprise non-profit created by Collins, called Phare Bio, now plans to advance these and other AI-discovered antibiotics toward clinical development.

The candidate antibiotics build on earlier finds from Collins’ lab—including halicin, a potent broad-spectrum antibiotic identified in 2020; a more targeted agent called abaucin with activity against Acinetobacter baumannii, a major cause of hospital-acquired infections; and a novel structural class of molecules described last year that proved effective against the superbugs MRSA and VRE.

With the team’s earlier discoveries, however, Collins and his colleagues were still mining existing chemical libraries, using deep-learning models to spot overlooked compounds with antibacterial potential. The new work sets down a new path altogether: rather than searching for hidden gems in familiar territory, the generative AI platform starts from scratch, conjuring entirely new molecular structures absent from any database.

“This is moving from using AI as a discovery tool to using AI as a design tool,” Collins says. The shift, he adds, opens new frontiers in antibiotic discovery—unexplored territory that could harbor the next generation of lifesaving drugs.

Anti-Germ Intelligence Proves Its Mettle

To train their generative AI model, Collins and his colleagues first used a neural network framework to virtually screen more than 45 million chemical fragments—the building blocks of would-be drugs—looking for pieces predicted to have activity against Neisseria gonorrhoeae (the cause of sexually transmitted gonorrhea infections) and Staphylococcus aureus (the germ behind deadly bloodstream infections, pneumonia, and flesh-eating skin disease). Two algorithms then went to work: one assembling the fragments into complete molecular structures, the other predicting which of those structures would pack the strongest antibacterial punch.

Together, the algorithms generated more than 10 million candidate molecules, none of which had ever existed before. But then came what MIT study author and computational biologist Aarti Krishnan describes as “a massive bottleneck”: very few of these prophesied antibiotics could actually be made in the lab.

The researchers manually sifted through the AI hits, filtering for properties suggestive of drug-likeness and synthetic feasibility. They ultimately arrived at a shortlist of around 200 promising designs, 24 of which could be successfully generated. Seven proved to be bona fide antimicrobial agents, as confirmed by laboratory tests, with two showing particularly strong efficacy in mouse models of gonorrhea and staph infections. Notably, each seems to work through a distinct and novel mechanism of action not exploited by existing antibiotics.

“That’s pretty cool,” says Phare co-founder Jonathan Stokes, an antimicrobial chemical biologist at Canada’s McMaster University in Hamilton, Ontario. He praises Collins’ team for unearthing two highly promising antibiotic leads but notes that the labor-intensive trial-and-error process underscores how far the technology still has to go in producing compounds that can be readily synthesized.

“It’s a bit of an elephant in the room,” he says of synthetic tractability in GenAI drug discovery. “Antibiotics, because of the financial disincentives in this space, have to be cheap,” Stokes, who was not involved in the research, says. “They have to be cheap to discover, cheap to develop, and cheap to make. So if there are opportunities to avoid all of these issues with synthetic feasibility, I feel like that is a major advantage.”

Moving From Model to Molecule

To tackle that challenge, Stokes and his colleagues developed a generative AI tool that designs antibiotic candidates with chemical blueprints tailored for real-world manufacturing, not just computer screens. This tool, called SyntheMol, operates within a more limited chemical space than Collins’ GenAI model, choosing only molecules whose building blocks can be synthesized with known, lab-proven reaction steps. That narrows the search parameters to tens of billions of molecules, compared to the 1060 possible structures that Collins’ model explored.

It’s enough, however, for SyntheMol to have already yielded several drug candidates that Stokes and his colleagues, through a startup called Stoked Bio, hope to develop into treatments for bacteria linked to Crohn’s disease and other hard-to-treat conditions.

The team aims to balance the sheer breadth of biochemical possibilities the models can explore with crucial metrics like drug potency, safety, low toxicity, and ease of synthesis. “It’s a multi-objective optimization problem,” says de la Fuente, who advises Phare and builds his own generative AI models to design antimicrobial peptide drugs.

But for now, the tools powering Phare’s discovery efforts—rooted in Collins’ approaches—are already delivering early wins, says Akhila Kosaraju, Phare Bio’s CEO and president. “We are getting substantially more potent and less toxic initial compounds,” she notes. And backed by the U.S. government’s Advanced Research Projects Agency for Health (ARPA-H), along with the philanthropic arm of Google—which is funding Phare to build open-source infrastructure around AI-guided antibiotic design— Kosaraju and her colleagues aim to move the most promising candidates into human trials.

“We are building what we think is the most novel and robust pipeline of antibiotics in the world,” she says.

Research Strengthens Case for Metabolic Advantages of L. paracasei

Research Strengthens Case for Metabolic Advantages of L. paracasei

Lacticaseibacillus paracasei NB23 supplementation significantly improved metabolic health, muscle mass, and lower limb strength in healthy adults, according to a 12-week randomized controlled trial. The study highlighted increased IGF-1 levels, better insulin sensitivity, and enhanced cardiometabolic markers, supporting NB23’s potential as a functional probiotic for metabolic resilience and muscle maintenance.